Open Beta
TREN
MetriLume
TREN

US marketsAXSM

SEC-sourced researchBeta

AXSM

Axsome Therapeutics, Inc.

Company comparison ↗

Data passport

CIK
0001579428
Exchange
Nasdaq
Business activity
Pharmaceutical Preparations · SIC 2834
Financial inputs
6/6
Filing date
Sep 3, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2023: 270,600,000.0000 USD; December 2024: 385,693,000.0000 USD; December 2025: 638,496,000.0000 USD638.5M USD0 USD0December 2023December 2024December 2025
AXSM · Exact amounts and source periods · USD
Period endRevenueFiling date
December 2023270,600,000.0000Feb 23, 2026
December 2024385,693,000.0000Feb 23, 2026
December 2025638,496,000.0000Feb 23, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 2025638,496,000.0000-183,174,000.0000-93,405,000.0000689,805,000.0000601,510,000.0000Feb 23, 2026
December 2024385,693,000.0000-287,216,000.0000-128,410,000.0000568,498,000.0000511,483,000.0000Feb 23, 2026
December 2023270,600,000.0000-239,238,000.0000-145,080,000.0000——Feb 23, 2026

Explainable fundamental score

Five equally weighted components based on SEC financial inputs. No price inputs or personal investment preferences.

47/100
Profitability0
Growth100
Balance sheet13
Cash generation21
Data coverage100

Component weight: 20% · Minimum data coverage: 50% · Missing component value: 50/100

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$638.5MJan 1, 2025 – Dec 31, 2025Feb 23, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$385.69MJan 1, 2024 – Dec 31, 2024Feb 23, 202610-K
Net incomeNetIncomeLoss-$183.17MJan 1, 2025 – Dec 31, 2025Feb 23, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$93.41MJan 1, 2025 – Dec 31, 2025Feb 23, 202610-K
Total assetsAssets$689.81MDec 31, 2025Feb 23, 202610-K
Total liabilitiesLiabilities$601.51MDec 31, 2025Feb 23, 202610-K

New filings

Explore methodology ↗